TRANSDERMAL patches loaded with pravastatin was previously characterized in another published study by Serrano-Castañ eda et al; 2015. These TRANSDERMAL patches (TP) were generated by the plate casting technique, the in-vitro percutaneous ABSORPTION studies of TP were evaluated for three different formulations with different quantities of Pluronic F-127 (PF-127): i) without PF-127 (TP W), ii) 1% of PF-127 (TP 1%), and iii) 3% of PF-127 (TP 3%) using solid microneedles as a penetration enhancer with two different lengths: i) 0. 25 mm and ii) 2. 25 mm and iii) in-vitro permeation studies by passive diffusion. The fluxes (F), time lag (tLag) and permeability constants (Kp) for each formulation were: TP W (F: 38. 5μ g/cm2*h, tLag: 18. 97h and Kp: 5. 9x10-3 cm/h), TP W with microneedles of 0. 25 mm (F: 103. 3 μ g/cm2*h, tLag: 20. 76 h and Kp: 0. 0158 cm/h), TP W and microneedles of 2. 25 mm (F: 105. 2μ g/cm2*h, tLag: 21. 16 h and Kp: 0. 0159cm/h), TP 1% (F: 90 μ g/cm2*h, tLag: 19. 48 h and Kp: 0. 0137 cm/h), TP 1% with microneedles of 0. 25 mm (F: 111. 4μ g/cm2*h, tLag: 19. 11h and Kp: 0. 017cm/h), and TP 1% with microneedles of 2. 25 mm (F: 115. 2μ g/cm2*h, tLag: 16. 73h and Kp: 0. 017cm/h), TP 3% (F: 40. 9μ g/cm2*h, tLag: 20. 45h and Kp: 0. 0062 cm/h), TP 3% with microneedles of 0. 25 mm (F: 67. 1 μ g/cm2*h, tLag: 21. 79h and Kp: 0. 0102cm/h) and TP 3% with microneedles of 2. 25 (F: 70. 5 μ g/cm2*h, tLag: 20. 44h and Kp: 0. 0107cm/h). Results show that the formulation of TP affects the pravastatina flux and Kp parameters, however the length of microneedles only has important effect on tLag.